This will play a video - Shock Reduction Hero image bumper car

FEWER SHOCKS. GREATER LIVING.

STEER PATIENT CLEAR

OF INAPPROPRIATE AND

UNNECESSARY SHOCKS WITH

SMARTER TECHNOLOGY

Defibrillators save lives but shocks can lead to patient pain and anxiety decreasing quality of life resulting in increased costs and resource usage of the healthcare system.

20 years ago, Medtronic decided to start a quest with the goal to ONLY SHOCK TO SAVE A LIFE.

Shock Reduction Data Squared shape

1.5%

Inappropriate shock rate in dual chamber and triple chamber ICD patients at one year.1

2.5%

Inappropriate shock rate in single chamber ICD patients at one year.1

52%

Further reduced shocks while using ATP during charging, along with 30/40 Long Detection Interval (LDI).2

2019 HRS/EHRA/APHRS/LAHRS EXPERT CONSENSUS PROGRAMMING GUIDELINES3

  • Nominal settings of Medtronic’s defibrillators are nearly identical to these guidelines
  • Only 3* recommendations differ from nominals:
    • VT NID = 24 (nominal is 16)
    • ATP before charging in the VF zone (nominal is during charging)
    • RV Lead Noise On without timeout (timeout is nominally on)

In contrast, the recommendations differed from other manufacturers’ nominal settings.

 

Shock Reduction Data Squared shape

NOMINALS MAKE AN IMPACT

ONLY 1/3

of devices programmed according to consensus document.20

 

Highest
PROPORTION

of ICDs programmed according to guidelines in Medtronic devices.20

 

38% LOWER RISK

Medtronic patients received significantly fewer ICD therapy compared to other device patients.20

Shock Reduction Timeline

ICDS & CRT-DS

Please visit our Medtronic website for more information on our ICD/CRT-D portfolio.

COMPLETE THE FORM AND A MEDTRONIC REPRESENTATIVE WILL BE IN TOUCH WITH MORE INFORMATION. 

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

View our privacy statement

REFERENCES

1. Auricchio A et al. Heart Rhythm 2015;12:926-936.
2. Arenal A et al. Europace 2016;18:1719–1725.
3. Stiles MK et al. Europace 2019;21:1442–1443.
4. Wilkoff BL et al. Circulation 2001;103(3):381-386.
5. Wathen MS et al. Circulation 2001;104:796-801.
6. Wathen MS et al. Circulation 2004;110;2591-2596
7. Klein GJ et al. J Cardiovasc Electrophysiol 2006;17:1310-1319.
8. Wilkoff BL et al. J Am Coll Cardiol 2006;48:330 –339.
9. Schoels W et al. Heart Rhythm 2007;4:879–885.
10. Wilkoff BL et al. J Am Coll Cardiol 2008;52:541–50.
11. Gasparini M et al. European Heart Journal (2009) 30, 2758–2767
12. Toquero J et al. Europace (2009) 11, 727–733
13. Gasparini M et al. Am Heart J 2010;159:1116-1123.
14. Santini M et al. J Interv Card Electrophysiol (2010) 27:127–135
15. Volosin KJ et al. J Cardiovasc Electrophysiol 2011;22:280–289.
16. Gasparini M et al. JAMA. 2013;309(18):1903-1911.
17. Silver MT et al. Heart Rhythm 2015;12:545-53.
18. Regoli F et al. BMC Cardiovascular Disorders (2019) 19:146
19. Cheng A et al. J Cardiovasc Electrophysiology. 2019;30(12):2877-2884.
20. Ananwattanasuk T, et al. Heart Rhythm 2020, advance access published Feb 2020

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu

* only 2 changes with CobaltTM & CromeTM devices.
One additional recommendation on CRTD’s: Adaptive BiV or LV for pts with intact AV conduction and LBBB (nominally on in Medtronic CRT devices).